A month after reporting positive data for cystic fibrosis (CF) candidate VX-770 in adult patients, Vertex Pharmaceuticals Inc. disclosed better-than-expected results in a separate study involving children ages 6 to 11, which should further bolster regulatory filings expected in the second half of this year.